SCHEDULE 13G/A: Major Shareholder Thomas Satterfield Jr. Discloses 8.2% Stake in BioCardia, Inc.

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.2% of BioCardia, Inc.'s common stock as of December 31, 2024.

Summary

• Thomas A. Satterfield, Jr. reported beneficial ownership of 388,147 shares of BioCardia, Inc. common stock.
• This ownership represents 8.2% of the company's outstanding common stock.
• The calculation is based on 4,584,285 shares of common stock outstanding as of November 5, 2024, as reported by BioCardia, Inc. in its Form 10-Q.
• The reported beneficial ownership includes the assumed exercise of 156,982 warrants held by Mr. Satterfield.
• This filing is Amendment No. 2 to the Schedule 13G, with the event date requiring the filing being December 31, 2024.
• Mr. Satterfield holds sole voting and dispositive power over 87,498 shares and shared voting and dispositive power over 300,649 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing factual beneficial ownership information, providing no inherent positive or negative sentiment regarding the company's performance or future prospects.

Positives

• A significant investor, Thomas A. Satterfield, Jr., maintains a substantial 8.2% beneficial ownership in BioCardia, Inc., indicating continued confidence in the company.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of the issuer, mitigating concerns about potential activist investor actions.

Future Outlook

The document is a regulatory filing disclosing beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard regulatory disclosure of a significant shareholder's stake and does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure of BioCardia, Inc.

Related Party Transactions

• 49,999 shares of common stock and 52,150 shares issuable upon exercise of warrants are held by Tomsat Investment & Trading Co., Inc., a corporation wholly owned by Mr. Satterfield, who serves as its President.
• 96,334 shares of common stock and 69,666 shares issuable upon exercise of warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.
• 30,000 shares are held by Caldwell Mill Opportunity Fund, LLC, which is managed by an entity where Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.
• Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to 2,500 shares held by Rebecca A. Satterfield, who retains the right to receive proceeds from the sale of her shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership of a significant investor, Thomas A. Satterfield, Jr., and his associated entities, confirming a substantial and stable stake in the company.

Key Dates

Keywords

BioCardia, BCDA, Thomas Satterfield, Schedule 13G, beneficial ownership, common stock, SEC filing, investment, shareholder